Low versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil

PLoS ONE

Volumn 12, Issue 5, 2017, Pages

  Saheki, Mauricio Naoto ^a   Lyra, Marcelo Rosandiski ^a   Bedoya Pacheco, Sandro Javier ^a,b   Antonio, Liliane De Fatima ^a   Pimentel, Maria Inês Fernandes ^a   Salgueiro, Mariza De Matos ^a   Vasconcellos, Erica De Camargo Ferreira E ^a   Passos, Sonia Regina Lambert ^a   Santos, Ginelza Peres Lima Dos ^a   Ribeiro, Madelon Novato ^a   Fagundes, Aline ^a   Madeira, Maria De Fatima ^a   Mouta Confort, Eliame ^a   Marzochi, Mauro Celio De Almeida ^a   Valete Rosalino, Claudia Maria ^a,c   Schubach, Armando De Oliveira ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

MEGLUMINE ANTIMONATE; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND;

ADOLESCENT; ADULT; AMERICAN CUTANEOUS LEISHMANIASIS; ARTICLE; BRAZIL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; EPITHELIZATION; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERAMYLASEMIA; LEISHMANIA BRAZILIENSIS; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; OTOTOXICITY; PANCREAS DISEASE; PARASITE CONTROL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SINGLE BLIND PROCEDURE; SKIN LEISHMANIASIS; LEISHMANIASIS, CUTANEOUS;

BRAZIL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEISHMANIASIS, CUTANEOUS; MEGLUMINE; ORGANOMETALLIC COMPOUNDS;

EID: 85019978796     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0178592     Document Type: Article

References (60)

1. Da-Cruz AM, Pirmez C. Leishmaniose tegumentar americana. In: Coura JR, editor. DinaÃmica das doencEäs infecciosas e parasita rias. 1 ed. Rio de Janeiro: Guanabara Koogan; 2005. p. 697-712.
2. Pace D. Leishmaniasis. J Infect. 2014; 69 Suppl 1:S10-8. https://doi.org/10.1016/j.jinf.2014.07.016PMID: 25238669.
3. ConceicEaö-Silva F, Alves CRA. Leishmanioses do Continente Americano. Rio de Janeiro: Fiocruz;2014. 521 p.
4. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 2006; 22(12):552-7. https://doi.org/10.1016/j.pt.2006.09.004 PMID: 17023215.
5. WHO Expert Committee on the Control of the Leishmaniases., World Health Organization. Control ofthe leishmaniases: Report of a meeting of the WHO Expert Commitee on the Control of Leishmaniases, Geneva, 22-26 March 2010. Geneva: World Health Organization; 2010. xiii, 186 p.
6. World Health Organization. Leishmaniasis in high-burden countries: An epidemiological update basedon data reported in 2014. Wkly Epidemiol Rec. 2016; 91(22):287-96. PMID: 27263128.
7. Rabello E. Les origines de la leishmaniose teÂgumentaire au Bre sil. Congrès des dermatologistes etsyphiligraphes de langue francEaïse; Juillet 1923; Strasbourg, France;1923.
8. Rabello E. Formes cliniques de la leishmaniose teÂgumentaire. Congrès de dermatologistes et syphiligraphesde langue francEaïse; Juillet 1923; Strasbourg, France;1923.
9. Brazil Ministry of Health. Indicadores e dados baÂsicos: Taxa de incidência da leishmaniose tegumentaramericana 2013 [5 June 2013]. http://dtr2004.saude.gov.br/sinanweb/tabnet/tabnetsinannet/lta/bases/ltabrnet.def.
10. World Health Organization. Control of the Leishmaniases: Report of a meeting of the WHO Expert Committee.Geneva, Switzerland: World Health Organization; 2010. 186 p.
11. Vianna G. Tratamento da leishmaniose tegumentar por injecEöes intravenosas de taÂrtaro eme tico. ArqBras Med. 1912; 4:426-8.
12. Brazil Ministry of Health. Manual de VigilaAñcia da Leishmaniose Tegumentar Americana. BrasõÂlia, DF:Editora do Ministe rio da SauÂde; 2010. p. 180.
13. Roberts WL, Berman JD, Rainey PM. In vitro antileishmanial properties of tri-A nd pentavalent antimonialpreparations. Antimicrob Agents Chemother. 1995; 39(6):1234-9. PMID: 7574507
14. Fontenele e Silva JS, Galvao TF, Pereira MG, Silva MT. Treatment of American tegumentary leishmaniasisin special populations: A summary of evidence. Rev Soc Bras Med Trop. 2013; 46(6):669-77.https://doi.org/10.1590/0037-8682-0104-2013 PMID: 24474006.
15. Schubach Ade O, Marzochi KB, Moreira JS, Schubach TM, Araujo ML, Vale AC, et al. Retrospectivestudy of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate. Rev Soc BrasMed Trop. 2005; 38(3):213-7./S0037-86822005000300001. PMID: 15895170.
16. Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C. Treatment of Americancutaneous leishmaniasis: A comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens. Pathol Biol (Paris). 1997; 45(6):496-9. PMID: 9309267.
17. Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C. A low-dose antimony treatmentin 159 patients with American cutaneous leishmaniasis: Extensive follow-up studies (up to 10years). Am J Trop Med Hyg. 1997; 57(6):651-5. PMID: 9430521.
18. Oliveira-Neto MP, Schubach A, Mattos M, da Costa SC, Pirmez C. Intralesional therapy of Americancutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazilan area of Leishmania(V.) braziliensis transmission. Int J Dermatol. 1997; 36(6):463-8. PMID: 9248897.
19. Oliveira-Neto MP, Mattos M, Pirmez C, Fernandes O, Goncalves-Costa SC, Souza CF, et al. Mucosalleishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime) in Rio deJaneiro, Brazil. Rev Inst Med Trop Sao Paulo. 2000; 42(6):321-5. PMID: 11136518.
20. Oliveira Neto MP, Schubach A, Araujo ML, Pirmez C. High and low doses of antimony (Sbv) in Americancutaneous leishmaniasis. A five years follow-up study of 15 patients. Mem Inst Oswaldo Cruz.1996; 91(2):207-9. PMID: 8736092.
21. de Camargo Ferreira EVE, de Oliveira Schubach A, Valete-Rosalino CM, de Souza Coutinho R, Conceicao-Silva F, de Matos Salgueiro M, et al. American tegumentary leishmaniasis in older adults: 44cases treated with an intermittent low-dose antimonial schedule in Rio de Janeiro, Brazil. J Am GeriatrSoc. 2010; 58(3):614-6. https://doi.org/10.1111/j.1532-5415.2010.02747.x PMID: 20398135.
22. Costa JM, Marsden PD. Low dose glucantime therapy in Leishmania viannia braziliensis (Lvb) infections.Rev Soc Bras Med Trop. 1988; 21(2):85-6. PMID: 3249826.
23. Amato VS, de Oliveira LS, Silva AC, Machado FR, Amato JG, Nicodemo AC, et al. [A case of mucocutaneousleishmaniasis treated with success with a low dose of pentavalent antimonial]. Rev Soc BrasMed Trop. 1998; 31(2):221-4. PMID: 9608241.
24. de Oliveira-Neto MP, Mattos Mda S. Successful therapeutic response of resistant cases of mucocutaneousleishmaniasis to a very low dose of antimony. Rev Soc Bras Med Trop. 2006; 39(4):376-8.PMID: 17119754.
25. Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, Magill A, et al. Methodology of clinical trials aimedat assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis. 2013; 7(3):e2130. https://doi.org/10.1371/journal.pntd.0002130 PMID: 23556016;
26. Ampuero JS. Efficacy and safety of low-dose pentavalent antimonial for treatment of cutaneous leishmaniasisby Leishmania (Viannia) braziliensis in Bahia, Brazil: A randomized clinical trial [Doctoral thesis].BrasõÂlia, DF: Universidade de BrasõÂlia; 2009.
27. Division of AIDS, National Institute of Allergy Infectious Diseases, National Institutes of Health. Divisionof AIDS table for grading the severity of adult and pediatric adverse events 2004 [12 May 2015]. http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table-for-Grading-Severity-of-Adult-Pediatric-Adverse-Events.pdf.
28. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate(Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J InfectDis. 1992; 165(3):528-34. PMID: 1311351.
29. Navin TR, Arana BA, Arana FE, de Merida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinicaltrial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneousleishmaniasis in Guatemala. Am J Trop Med Hyg. 1990; 42(1):43-50. PMID: 2405727.
30. Mattos MdS. DeterminacEaö de paraÃmetros clõÂnicos e prognoÂsticos para o controle de cura da LeishmanioseTegumentar Americana [Doctoral thesis]. Rio de Janeiro, RJ: FundacEaö Oswaldo Cruz; 2004.
31. Food and Drug Administration, U.S. Department of Health and Human Services. Guidance for Industry:non-Inferiority clinical trials. Rockville, MD: Food and Drug Administration; 2010. 63 p.
32. Nelson W. Applied life data analysis. New York: Wiley; 1982. xiv, 634 p.
33. Cupolillo E, Grimaldi G Jr., Momen H. A general classification of New World Leishmania using numericalzymotaxonomy. Am J Trop Med Hyg. 1994; 50(3):296-311. PMID: 8147488.
34. Antonio LdF. Resposta à IntradermorreacEaö de Montenegro e ocorrência de falha terapeûtica na formacutaAñea da leishmaniose tegumentar americana: Um estudo de caso controle [Master's dissertation].Rio de Janeiro, RJ: FundacEaö Oswaldo Cruz; 2012.
35. Oliveira AL, Brustoloni YM, Fernandes TD, Dorval ME, Cunha RV, Boia MN. Severe adverse reactionsto meglumine antimoniate in the treatment of visceral leishmaniasis: A report of 13 cases in the southwesternregion of Brazil. Trop Doct. 2009; 39(3):180-2. https://doi.org/10.1258/td.2008.080369 PMID:19535762.
36. Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, et al. Systematic reviewof the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop. 2011; 118(2):87-96. https://doi.org/10.1016/j.actatropica.2011.02.007 PMID: 21420925.
37. Sundar S, Chakravarty J. Antimony toxicity. Int J Environ Res Public Health. 2010; 7(12):4267-77.https://doi.org/10.3390/ijerph7124267 PMID: 21318007;
38. Chulay JD, Spencer HC, Mugambi M. Electrocardiographic changes during treatment of leishmaniasiswith pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg. 1985; 34(4):702-9. PMID:2992303.
39. Neves DB, Caldas ED, Sampaio RN. Antimony in plasma and skin of patients with cutaneous leishmaniasisrelationship with side effects after treatment with meglumine antimoniate. Trop Med Int Health.2009; 14(12):1515-22. https://doi.org/10.1111/j.1365-3156.2009.02408.x PMID: 19954451.
40. Diniz DS, Costa AS, Escalda PM. The effect of age on the frequency of adverse reactions caused byantimony in the treatment of American tegumentary leishmaniasis in Governador Valadares, State ofMinas Gerais, Brazil. Rev Soc Bras Med Trop. 2012; 45(5):597-600. PMID: 23152343.
41. Martinez JE, Travi BL, Valencia AZ, Saravia NG. Metastatic capability of Leishmania (Viannia) panamensisand Leishmania (Viannia) guyanensis in golden hamsters. J Parasitol. 1991; 77(5):762-8.PMID: 1919926.
42. Mohapatra S. Drug resistance in leishmaniasis: Newer developments. Trop Parasitol. 2014; 4(1):4-9.https://doi.org/10.4103/2229-5070.129142 PMID: 24754020;
43. Grimaldi G Jr., Porrozzi R, Friedrich K, Teva A, Marchevsky RS, Vieira F, et al. Comparative efficaciesof two antimony regimens to treat Leishmania braziliensis-induced cutaneous Leishmaniasis in rhesusmacaques (Macaca mulatta). Antimicrob Agents Chemother. 2010; 54(1):502-5. https://doi.org/10.1128/AAC.00858-09 PMID: 19822700;
44. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, da Silva RM, Gadelha Yamashita EP, de OliveiraPenna G, et al. Randomized controlled clinical trial to access efficacy and safety of miltefosine in thetreatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.Am J Trop Med Hyg. 2011; 84(2):255-60. https://doi.org/10.4269/ajtmh.2011.10-0155 PMID:21292895;
45. Machado PR, Ampuero J, Guimaraes LH, Villasboas L, Rocha AT, Schriefer A, et al. Miltefosine in thetreatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: A randomized andcontrolled trial. PLoS Negl Trop Dis. 2010; 4(12):e912. https://doi.org/10.1371/journal.pntd.0000912PMID: 21200420;
46. Drugs for Neglected Diseases initiative (DNDi). Leishmaniasis factsheet 2015 [cited 2016 November 6, 2016]. http://www.dndi.org/wp-content/uploads/2016/10/Factsheet-2015-Leish.pdf.
47. Cardona-Arias JA, Velez ID, Lopez-Carvajal L. Efficacy of thermotherapy to treat cutaneous leishmaniasis:a meta-analysis of controlled clinical trials. PLoS One. 2015; 10(5):e0122569. https://doi.org/10.1371/journal.pone.0122569 PMID: 26009885;
48. Herwaldt BL. Leishmaniasis. Lancet. 1999; 354(9185):1191-9. https://doi.org/10.1016/S0140-6736(98)10178-2 PMID: 10513726.
49. Blum J, Lockwood DN, Visser L, Harms G, Bailey MS, Caumes E, et al. Local or systemic treatment forNew World cutaneous leishmaniasis Re-evaluating the evidence for the risk of mucosal leishmaniasis.Int Health. 2012; 4(3):153-63. https://doi.org/10.1016/j.inhe.2012.06.004 PMID: 24029394.
50. Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg. 1986;80(6):859-76. PMID: 3037735.
51. Brahim-Paes LRdN. DistribuicEaö espacEötemporal dos casos humanos de leishmaniose tegumentaramericana notificados no estado do Rio de Janeiro de 2001 a 2013 e associacEaö com variaÂveis clõÂnicase populacionais [Doctoral thesis]. Rio de Janeiro, RJ: FundacEaö Oswaldo Cruz; 2016.
52. Lakhal-Naouar I, Slike BM, Aronson NE, Marovich MA. The Immunology of a Healing Response inCutaneous Leishmaniasis Treated with Localized Heat or Systemic Antimonial Therapy. PLoS NeglTrop Dis. 2015; 9(10):e0004178. https://doi.org/10.1371/journal.pntd.0004178 PMID: 26485398;
53. McCormack JP, Allan GM, Virani AS. Is bigger better An argument for very low starting doses. CMAJ.2011; 183(1):65-9. https://doi.org/10.1503/cmaj.091481 PMID: 20921252;
54. Chin R, Lee BY. Dosing and intervention. Principles and Practice of Clinical Trial Medicine. 1 ed.Amsterdam: Elsevier Academic Press; 1996. p. 181-212.
55. Neumann PJ. Using cost-effectiveness analysis to improve health care: Opportunities and barriers.Oxford; New York: Oxford University Press; 2005. xii, 209 p. p.
56. World Health Organization., Baltussen RMPM, Adam T, Tan-Torres Edejer T, Hutubessy RCW, Acharya A, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: WorldHealth Organization; 2003. 318 p. + 1 CD-ROM. p.
57. Rio de Janeiro Municipal Secretary of Health. Leishmaniose tegumentar americana: InvestigacEaöSINAN-NET 10.05.2012. Rio de Janeiro, RJ: Sanitary Dermatology Management; 2012.
58. Azeredo-Coutinho RB, Mendonca SC, Callahan H, Portal AC, Max G. Sensitivity of Leishmania braziliensispromastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmaniaspecies and correlates with response to therapy in American tegumentary leishmaniasis. J Parasitol.2007; 93(3):688-93. https://doi.org/10.1645/GE-1031R.1 PMID: 17626365.
59. Yardley V, Ortuno N, Llanos-Cuentas A, Chappuis F, Doncker SD, Ramirez L, et al. American tegumentaryleishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility J Infect Dis.2006; 194(8):1168-75. https://doi.org/10.1086/507710 PMID: 16991093.
60. Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneousand mucocutaneous leishmaniasis. Cochrane Database Syst Rev. 2009;(2):CD004834. https://doi.org/10.1002/14651858.CD004834.pub2 PMID: 19370612.